

AMENDMENTS TO THE CLAIMS

The following is a complete listing of claims with a status identifier in parentheses.

LISTING OF CLAIMS

1. (CURRENTLY AMENDED) A ~~drug~~substance carrier ~~that comprises~~ing hollow nanoparticles of a particle-forming protein, the hollow nanoparticles displaying an antibody against a specific cell or specific tissue, and encapsulating a substance to be transferred into a cell for treating a disease,

the antibody being a cancer specific antibody or anti-virus protein antibody,
and
the particle-forming protein including a modified hepatitis B virus surface-antigen L-protein.

2. (CANCELLED).

3. (CURRENTLY AMENDED) The ~~drug~~substance carrier as set forth in claim 1, wherein the antibody is displayed on a particle surface by binding to a ZZ tag fused with the particle-forming protein.

4. (CANCELLED).

5. (CURRENTLY AMENDED) The substance carrier ~~drug~~ as set forth in claim 1,

wherein the antibody is a single chain antibody fused with the particle-forming protein.

6. (CURRENTLY AMENDED) The substance carrier drug as set forth in claim 1, wherein the hollow nanoparticles of a particle-forming protein are expressed in a eukaryotic cell.

7. (CURRENTLY AMENDED) The substance carrier drug as set forth in claim 6, wherein the eukaryotic cell is selected from a group consisting of a yeast cell, insect cell, and animal cell.

8. (CANCELLED).

9. (CURRENTLY AMENDED) The substance carrier drug as set forth in claim 8~~1~~, wherein the modified hepatitis B virus surface-antigen L protein is modified to lack some of amino acids in a pre-S region.

10-13. (CANCELLED).

14. (CURRENTLY AMENDED) The substance carrier drug as set forth in claim 1, wherein the disease-treating substance comprises a gene.

15. (CURRENTLY AMENDED) The substance carrier drug as set forth in claim

14, wherein the gene comprises a thymidine kinase (HSV1tk) gene derived from simple herpes virus.

16-21. (CANCELLED).

22. (CURRENTLY AMENDED) The substance carrier ~~drug~~ as set forth in claim 21, wherein the antibody is displayed on a particle surface by binding to a ZZ tag fused with the particle-forming protein.

23. (CANCELLED).

24. (CURRENTLY AMENDED) The substance carrier ~~drug~~ as set forth in claim 21, wherein the antibody is a single chain antibody fused with the particle-forming protein.

25. (CURRENTLY AMENDED) The substance carrier ~~drug~~ as set forth in claim 21, wherein the hollow nanoparticles of a particle-forming protein are expressed in a eukaryotic cell.

26-28. (CANCELLED).

* * * * *